Pfizer CEO Ian Read contends that the company’s pipeline is strong enough to fuel growth, even after its second-best-selling product, Lyrica, goes off the patent cliff. In other words, don’t look for a “transformative” deal. More: No need for a
read moreMerck’s checkpoint inhibitor Keytruda brought in sales of $1.46 billion in the first quarter—a whopping 151% growth and way ahead of Street projections. But that didn’t stop analysts from hammering CEO Ken Frazier about Merck’s plans to get some new
read moreYears after federal officials failed to win a guilty verdict against former Warner Chilcott president W. Carl Reichel, a doctor involved hasn’t been so fortunate. Dr. Rita Luthra was convicted Monday in a Warner marketing scheme—and in more evidence that
read moreBill Gates, with support from Google co-founder Larry Page, is so set on staving off a deadly flu pandemic that he’s set up a challenge to develop a universal shot. What will it take? Hint: Innovative concepts or technologies not
read moreIndia’s drug regulatory force, the Central Drugs Standards Control Organization, pulled off a third round of raids on drug facilities that were manufacturing products without approval. More: India’s drug regulatory force conducts third round of raids on manufacturers Source: fierce
read moreIf approved by the FDA, this would mark the third indication for Keytruda in metastatic NSCLC in the United States based on OS data More: FDA grants Keytruda priority review Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals